DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced that in vivo data highlighting the enhanced efficacy of Lantern’s drug candidate LP-184 in glioblastoma (GBM) were published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

DALLAS-（BUSINESS WIRE）-Lantern Pharma Inc.（纳斯达克股票代码：LTRN），一家人工智能（AI）公司，利用其专有的AI和机器学习（ML）平台RADR®开发靶向和变革性癌症疗法，多个临床阶段药物项目，今天宣布，突出Lantern候选药物LP-184在胶质母细胞瘤（GBM）中增强功效的体内数据发表在美国癌症研究协会杂志Clinical Cancer Research上。

LP-184 is a unique small molecule with low nanomolar activity and favorable CNS penetration. LP-184 utilizes its powerful mechanism of action, known as synthetic lethality, to exploit common vulnerabilities in solid tumor and CNS cancers with DNA damage repair (DDR) deficiencies. In addition, Lantern’s AI platform, RADR®, has highlighted overlapping gene dependency profiles between GBM tumorigenesis and sensitivity to LP-184, such as EGFR activation pathways..

LP-184是一种独特的小分子，具有低纳摩尔活性和良好的CNS渗透性。LP-184利用其强大的作用机制（称为合成致死性）来利用DNA损伤修复（DDR）缺陷的实体瘤和CNS癌症中的常见脆弱性。此外，Lantern的AI平台RADR®突出了GBM肿瘤发生与LP-184敏感性（如EGFR激活途径）之间重叠的基因依赖性谱。。

“The data highlighted in Clinical Cancer Research solidify LP-184 as a promising therapeutic for GBM, with LP-184 having inhibited the viability and growth of multiple GBM models including temozolomide-resistant and MGMT-expressing cells,” stated Panna Sharma, Lantern's President and CEO. “The rapid advancement of LP-184 into a first-in-human Phase 1 trial provides strong validation of the power of our AI-enabled approach to drug development.

“临床癌症研究中突出显示的数据巩固了LP-184作为GBM的有希望的治疗方法，LP-184抑制了多种GBM模型的活力和生长，包括替莫唑胺耐药和MGMT表达细胞，”Lantern的Panna Sharma说。总裁兼首席执行官。“LP-184迅速发展成为人体第一阶段试验，为我们的AI药物开发方法的强大功能提供了有力的验证。

This approach is about more than just developing new treatments, it’s about making them more targeted, more effective, and ultimately doing all of this more efficiently. This publication demonstrates our ability to deliver on these aspirations and introduce new therapeutic programs in areas where there is significant unmet patient need.”.

这种方法不仅仅是开发新的治疗方法，还在于使它们更有针对性，更有效，并最终更有效地完成所有这些工作。本出版物展示了我们实现这些愿望的能力，并在患者需求未得到满足的领域引入新的治疗方案。

The article, entitled “Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma” can be accessed here.

可以在这里访问题为“LP-184，一种肿瘤部位激活的合成致死治疗剂，在胶质母细胞瘤中的临床前功效”的文章。

A Phase 1 clinical trial (NCT05933265) evaluating LP-184 in patients with advanced solid tumors is underway. The single arm multicenter trial is assessing the safety and tolerability of escalating doses of LP-184 to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with advanced solid tumors and recurrent high-grade gliomas, including GBM.

正在进行一项评估LP-184治疗晚期实体瘤患者的1期临床试验（NCT05933265）。单臂多中心试验正在评估递增剂量的LP-184的安全性和耐受性，以确定晚期实体瘤和复发性高级别胶质瘤患者的最大耐受剂量（MTD）和推荐的2期剂量（RP2D），包括GBM。

The study has been designed as a 35 patient trial with patients receiving LP-184 infusion on Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, pharmacokinetics, and clinical activity, and dose escalation is planned with a minimum of three patients per cohort.

该研究设计为35名患者试验，患者在每个21天周期的第1天和第8天接受LP-184输注，至少两个周期。将监测患者的安全性，药代动力学和临床活动，并计划剂量递增，每个队列至少三名患者。

Lantern anticipates the Phase 1A portion of the trial to be completed in the first half of 2024 and a Phase 2 trial in GBM and other CNS cancers to begin in the second half of 2024. The anticipated Phase 2 trial will be conducted by Starlight Therapeutics, a wholly owned subsidiary of Lantern focused entirely on CNS and brain cancer indications.

Lantern预计试验的1A期部分将于2024年上半年完成，GBM和其他CNS癌症的2期试验将于2024年下半年开始。预计的第二阶段试验将由LANTER的合资子公司Starlight Therapeutics进行，该公司完全专注于中枢神经系统和脑癌适应症。

Lantern estimates that LP-184 has a global aggregate market potential of approximately $11-13 billion, consisting of $6-7 billion for solid tumors and $5-6 billion for CNS cancers..

Lantern估计LP-184的全球总市场潜力约为111-13亿美元，其中实体瘤为60-7亿美元，中枢神经系统癌症为5-6亿美元。。

About LP-184:

关于LP-184：

LP-184 is a unique small molecule that utilizes its powerful mechanism of action, known as synthetic lethality, to exploit common vulnerabilities in solid tumor and CNS cancers with DNA damage repair (DDR) deficiencies. The anti-tumor potential of LP-184 has been demonstrated across an extensive number of in-vitro and in-vivo cancer models, including pancreatic, prostate, lung, triple-negative breast cancer (TNBC), glioblastoma (GBM), brain metastases, and ATRT.

LP-184是一种独特的小分子，利用其强大的作用机制，称为合成致死率，利用DNA损伤修复（DDR）缺陷的实体瘤和CNS癌症的常见脆弱性。LP-184的抗肿瘤潜力已在广泛的体外和体内癌症模型中得到证实，包括胰腺癌，前列腺癌，肺癌，三阴性乳腺癌（TNBC），胶质母细胞瘤（GBM），脑转移瘤和ATRT。

In addition to LP-184’s promise as a single agent, its antitumor potency has the potential to be enhanced when used in combination with existing FDA-approved agents and other treatment modalities including spironolactone, PARP inhibitors, and radiation therapy. Results validating LP-184’s anti-tumor potential have been published at leading conferences and journals including, the American Association for Cancer Research (AACR) annual meeting, Clinical Cancer Research, an AACR journal, the Society for Neuro-Oncology annual meeting, the San Antonio Breast Cancer Symposium, and the Frontiers in Drug Discovery Journal..

除了LP-184作为单一药物的前景之外，当与现有的FDA批准的药物和其他治疗方式（包括螺内酯，PARP抑制剂和放射疗法）组合使用时，其抗肿瘤效力有可能增强。验证LP-184抗肿瘤潜力的结果已发表在领先的会议和期刊上，包括美国癌症研究协会（AACR）年会，临床癌症研究，AACR期刊，神经肿瘤学会年会，圣安东尼奥乳腺癌研讨会和药物发现前沿杂志。。

About Lantern Pharma:

关于Lantern Pharma：

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) RADR® platform leverages over 34 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development.

Lantern Pharma（纳斯达克股票代码：LTRN）是一家改变肿瘤药物发现和开发成本，步伐和时间表的AI公司。我们专有的AI和机器学习（ML）RADR®平台利用超过340亿个以肿瘤学为重点的数据点和200多种先进ML算法库，帮助解决肿瘤学药物开发中数十亿美元的现实问题。

By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per indication focused program..

通过利用人工智能的力量以及来自世界级科学顾问和合作者的投入，我们加速了我们不断增长的治疗方案的发展，包括11种癌症适应症和抗体-药物偶联物（ADC）计划。平均而言，我们新开发的药物计划已在2-3年内从最初的AI见解推进到首次人体临床试验，每个以适应症为重点的计划约为1.0-2.0百万美元。。

Our lead development programs include two Phase 2 clinical programs and recently initiated Phase 1 clinical programs for two additional product candidates with potential in multiple important cancer indications. We have also established a wholly-owned subsidiary, Starlight Therapeutics Inc., to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options.

我们的领先开发计划包括两个2期临床计划和最近启动的1期临床计划，用于两个可能具有多种重要癌症适应症的候选产品。我们还建立了一个国有子公司Starlight Therapeutics Inc.，专门致力于我们对中枢神经系统和脑癌的有希望的疗法的临床实施，其中许多疗法没有有效的治疗选择。

Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world..

我们的人工智能驱动的创新产品候选管道估计每年的综合市场潜力超过150亿美元，并有可能为全球数十万癌症患者提供改变生活的疗法。。

Please find more information at:

请在以下网址找到更多信息：

Website: www.lanternpharma.com

网址：www.lanternpharma.com

LinkedIn: https://www.linkedin.com/company/lanternpharma/

LinkedIn: https://www.linkedin.com/company/lanternpharma/

X/Twitter: @lanternpharma

X/推特：@lanternpharma

Newsletter – The Spark: Sign-up here

通讯-火花：在这里注册

Forward-looking Statements:

前瞻性声明：

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and biomarker data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others.

本新闻稿包含1933年“证券法”第27A条（经修订）和1934年“证券交易所法”第21E条（经修订）含义内的前瞻性声明。这些前瞻性陈述除其他外还包括与以下方面有关的陈述：未来事件或我们未来的财务业绩；我们的RADR®平台在识别可能对候选药物有反应的候选药物和患者群体方面的潜在优势；我们推进候选药物和抗体-药物偶联物（ADC）开发计划发展的战略计划；关于我们的候选药物和ADC开发计划的开发时间的估计；关于临床试验时间和患者登记的期望和估计；我们的内部药物发现计划的研发工作以及利用我们的RADR®平台来简化药物开发过程；我们打算利用人工智能，机器学习和生物标志物数据来简化和改变肿瘤药物发现和开发的速度，风险和成本，并确定可能对候选药物有反应的患者人群；关于患者人群，潜在市场和潜在市场规模的估计；我们的候选药物的销售估算以及我们通过自己或与他人合作推进此类候选药物来发现和开发候选药物并最大限度地发挥其商业潜力的计划。

Any statements that are not statements of historical fact (including, without limitation, statements that use words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,.

任何不是历史事实陈述的陈述（包括但不限于使用诸如“预期”，“相信”，“考虑”，“可以”，“估计”，“期望”，“意图”，“寻求，“，”可能“，”计划“，”潜力“，”预测“，”项目“，”目标“，。